BUZZ-Capricor Therapeutics rises on meeting with US FDA for muscle disorder therapy
Reuters
Aug 08
BUZZ-Capricor <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises on meeting with US FDA for muscle disorder therapy
** Shares of therapy developer Capricor Therapeutics CAPR.O up 3.22% at $8.33 premarket
** Co says meeting with U.S. FDA has been scheduled to discuss regulatory path of its cell therapy for treatment of cardiomyopathy associated with Duchenne muscular dystrophy, which is type of muscle disorder
** To accommodate this meeting, co has rescheduled release of its Q2 results to August 11 from August 12
** FDA in July declined to approved Deramiocel, saying the therapy does not meet efficacy requirements and asked for more data
** Up to last close, stock down 41.5% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.